Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer
29 mai 2020 08h30 HE
|
Celsion CORP
Excellent Surgical Response Noted at the Higher, 100 mg/m2 Dose Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...
Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
15 mai 2020 08h00 HE
|
Celsion CORP
Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J, May 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation...
Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020
08 mai 2020 09h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the first...
Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program
23 avr. 2020 08h30 HE
|
Celsion CORP
Added Capital Strengthens Balance Sheet, Assures Cash Through Major Phase III OPTIMA Study Data Readout Events Sale of an Additional $2.0 Million of NOL’s Expected in the 4th Quarter of 2020 ...
Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
15 avr. 2020 08h30 HE
|
Celsion CORP
Independent Data Monitoring Committee is Expected to Meet in July 2020 to Evaluate Overall Survival Data LAWRENCEVILLE, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm
26 mars 2020 08h00 HE
|
Celsion CORP
Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage...
Celsion Corporation Reports 2019 Financial Results and Provides Business Update
25 mars 2020 16h15 HE
|
Celsion CORP
Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020 LAWRENCEVILLE, N.J., March ...
Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency
23 mars 2020 08h00 HE
|
Celsion CORP
Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe LAWRENCEVILLE, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading...
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020
19 mars 2020 08h30 HE
|
Celsion CORP
Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., March 19, 2020 (GLOBE NEWSWIRE) -- Celsion...
Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer
19 mars 2020 08h00 HE
|
Celsion CORP
R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to Proceed with Phase II...